Primetime Life Sciences Awarded Phase II Fast Track SBIR Grant from NIAID

GERMANTOWN, Md. - Aug. 17, 2023 - PRLog -- Primetime Life Sciences, LLC, a leading pharmaceutical company committed to innovative treatment discovery and development, has announced its receipt of a Phase II Fast-Track Small Business Innovation Research (SBIR) grant. The award, conferred by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will aid in the development of a novel treatment for giardiasis.  Primetime Life Sciences is expected to receive up to $2.63 million over three years under this grant award (4R44AI165220-02).

Giardia lamblia, a waterborne human parasite that inflicts 1.2 million people annually worldwide, is classified as a category B bioterrorism organism. The current drugs have severe undesirable side effects and develop resistance to giardia lamblia strains. The goal of this project is to develop a potent MetAP2 inhibitor of a new chemical class and a novel mechanism of action to treat giardiasis.

The Fast Track SBIR grant includes two phases, with Primetime Life Sciences notably surpassing the Phase I milestones. Progressing to Phase II, the company will now conduct key pre-clinical studies, preparing for the submission of an Investigational New Drug (IND) application for their lead compound.

"We are thrilled to share that our lead compound demonstrated a promising safety profile in the Phase I part of the FastTrack SBIR award, indicating its potential as a giardiasis treatment," said Dr. Janak Padia, President and CEO of Primetime Life Sciences. "Backed by the non-dilutive SBIR funding, we are now able to concentrate on IND-enabling studies for this compound. The urgent need for more effective, safer treatments for giardiasis, especially resistant strains, cannot be overstated, and our research is committed to addressing this significant health issue."

About Primetime Life Sciences, LLC

Primetime Life Sciences (https://www.primetimelifesci.com) is a Maryland-based discovery and development company with a focus on small-molecule drugs. With a comprehensive "bench-to-bedside" approach, the company seeks to expedite the discovery and development of smart treatments. The company's innovation extends to a mutual prodrug platform using the "Metformin Linker Kit," enhancing the pharmacokinetic and safety profiles of known drugs. The company's extensive pipeline includes therapeutic solutions for central nervous system disorders, cancer, and parasitic infections.